Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Share-based Compensation (2023 - 2025)

Metagenomi (MGX) has disclosed Share-based Compensation for 3 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 21.04% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 million, a 26.85% decrease, with the full-year FY2025 number at $11.9 million, down 26.85% from a year prior.
  • Share-based Compensation was $2.7 million for Q4 2025 at Metagenomi, down from $3.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.1 million in Q1 2024 to a low of $529000.0 in Q1 2023.
  • A 3-year average of $2.9 million and a median of $3.1 million in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 855.95% in 2024, then tumbled 42.1% in 2025.
  • Metagenomi's Share-based Compensation stood at $2.5 million in 2023, then surged by 38.19% to $3.4 million in 2024, then fell by 21.04% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Share-based Compensation are $2.7 million (Q4 2025), $3.0 million (Q3 2025), and $3.2 million (Q2 2025).